Currently, significant strides have been made in T cell-based immunotherapy for cancer treatment since ipilimumab, an anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody, was approved by FDA for use in melanoma treatment. Here, CTLA4 is linked to melanoma.